Results of the European Society of Toxicologic Pathology Survey on the Use of Artificial Intelligence in Toxicologic Pathology.

Journal: Toxicologic pathology
Published Date:

Abstract

The European Society of Toxicologic Pathology (ESTP) initiated a survey through its Pathology 2.0 workstream in partnership with sister professional societies in Europe and North America to generate a snapshot of artificial intelligence (AI) usage in the field of toxicologic pathology. In addition to demographic information, some general questions explored AI relative to (1) the current status of adoption across organizations; (2) technical and methodological aspects; (3) perceived business value and finally; and (4) roadblocks and perspectives. AI has become increasingly established in toxicologic pathology with most pathologists being supportive of its development despite some areas of uncertainty. A salient feature consisted of the variability of AI awareness and adoption among the responders, as the spectrum extended from pathologists having developed familiarity and technical skills in AI, to colleagues who had no interest in AI as a tool in toxicologic pathology. Despite a general enthusiasm for these techniques, the overall understanding and trust in AI algorithms as well as their added value in toxicologic pathology were generally low, suggesting room for the need for increased awareness and education. This survey will serve as a basis to evaluate the evolution of AI penetration and acceptance in this domain.

Authors

  • Xavier Palazzi
    Pfizer Inc., Groton, Connecticut, USA.
  • Erio Barale-Thomas
    50148Janssen Pharmaceutica NV, Janssen R&D, Beerse, Belgium.
  • Bhupinder Bawa
    AbbVie, Preclinical Safety, North Chicago, IL, USA.
  • Jonathan Carter
    Labcorp Early Development Laboratories, Harrogate, UK.
  • Kyathanahalli Janardhan
    Merck & Co., Inc., Rahway, New Jersey, USA.
  • Heike Marxfeld
    5184BASF SE, Ludwigshafen, Rheinland-Pfalz, Germany. Carboni is now with the JOHNSON AND JOHNSON, Beerse, Antwerp, Belgium.
  • Abraham Nyska
    Toxicologic Pathology, Tel Aviv University, Timrat, Israel.
  • Chandrassegar Saravanan
    Novartis, Novartis Institutes for Biomedical Research, Preclinical Safety, Cambridge, MA, USA.
  • Dirk Schaudien
    Fraunhofer Institute for Toxicology and Experimental Medicine, Hanover, Germany.
  • Vanessa L Schumacher
    Roche Pharma Research and Early Development, Basel, Switzerland.
  • Robert H Spaet
    RSPathologics, LLC, Bend, Oregon, USA.
  • Simone Tangermann
    Badische Anilin- und Sodafabrik, Ludwigshafen, Germany.
  • Oliver C Turner
    Novartis, Novartis Institutes for Biomedical Research, Preclinical Safety, East Hanover, NJ, USA.
  • Enrico Vezzali
    Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.